Evidence for Health Improvement in People With Diabetes Using One Touch & Partner Solutions (ECLIPSE)
试验速览
- 阶段
- 不适用
- 发起方
- LifeScan
- 入组人数
- 800
- 试验地点
- 2
- 主要终点
- Changes in A1c from screening to 3 and 6 months in each of the OneTouch Solutions programs
研究概览
简要总结
ECLIPSE will evaluate the clinical and economic value of OneTouch Solutions in a real world study design. OneTouch Solutions describes a selection of devices and health and wellness solutions that people with diabetes (PWDs) can access online via OneTouch Solutions (Cecelia Health, Fitbit, Noom or Welldoc, each in combination with OneTouch Verio Reflect® blood glucose meter and the OneTouch Reveal® mobile app (or Welldoc app for the Welldoc arm)). ECLIPSE is a large parallel arm digital health study combining advanced blood glucose monitoring solutions with a choice of four different health and wellness applications or services. There are four unique study arms that will run in parallel over one year. The primary (A1c) endpoint for each study arm will be after 6 months and subjects will continue to use the interventions for a full year to generate data on sustained engagement with these products and services, and to collect healthcare utilization and health insurance claims information. Each study arm will differ to some degree in terms of patient baseline demographics (since subjects self-select their own app/intervention) and the experience per arm will be unique, and therefore each study arm will be analysed separately in terms of endpoints and outcomes.
详细描述
ECLIPSE (Evidence for health improvement in people with diabetes using One Touch & Partner Solutions) is a large parallel arm digital health study that will allow people with diabetes (PWDs) the freedom to choose the solution that is right for them, rather than forcibly randomize subjects to a specific study intervention. The intention of this real world study design is to mimic the choice PWDs will have when selecting a diabetes & digital health solution from the OneTouch Solutions website.
A target of 800 people with type 2 diabetes (PwT2Ds) will be recruited and offered one of four interventions with the aim of following 200 PWDs per study arm. Subjects in all four study arms will use a bluetooth connected OneTouch Verio Reflect blood glucose meter (BGM) which features a dynamic color range indicator (DCRI) and blood sugar mentor (BSM) insights. Subjects in three of the four study arms will also sync their Reflect BGM to the OneTouch Reveal (OTR) mobile diabetes app to enable further insights (PWDs in the Welldoc study arm will not use the OTR app).
The 4 unique study arms will also offer PWDs one of the following Partner offerings;
- Cecelia Health, which offers guidance from certified Diabetes Care and Education Specialists
- Fitbit, which offers activity and wellbeing insight from use of the Fitbit Inspire 2 tracker, and Fitbit Premium subscription
- Noom, a psychology-based weight and wellness program
- Welldoc, which offers personalized health coaching on multiple conditions, namely prediabetes, diabetes, hypertension and heart failure
ECLIPSE will gather glycemic measures, medication adherence, a variety of patient reported outcomes and partner app usage and app engagement analytics over one year. Health economic data (HECON) from PWDs from the year of participation in ECLIPSE will be analysed from a purchased dataset and a comparison will be made to HECON data from the same PWDs for the year prior to taking part in the study. In addition, a matched control group of PwT2D from the same purchased dataset will be compared to the data from all four study arms.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Self reports a diagnosis of type 2 diabetes
- •HbA1c ≥7.5% but ≤12% at screening
- •Currently instructed by a health care provider (HCP) to use a blood glucose meter to test blood sugar
- •Has a compatible smartphone and willing to redownload apps if they change phones during the study
- •Has a stable and consistent home and/or office internet connection
- •Currently on at least 1 oral (by mouth) or injected anti-diabetic medication (for lowering your blood glucose) with or without insulin therapy (insulin injections or an insulin pump) at screening
排除标准
- •Currently pregnant or planning to be pregnant in the next 12 months
- •Body Mass Index < 27
- •Currently using a CGM (Continuous glucose monitor) or have used a personal CGM in the past 3 months
- •Currently using a OneTouch Verio Reflect meter
- •For FitBit arm only: Currently uses related fitness applications (e.g., MyFitnessPal, JEFIT, Fitness Coach, Yoga-Go, etc.) or wearable device (e.g., Fitbit, Apple Watch, Garmin, Withings, etc.) in the past 6 months
结局指标
主要结局
Changes in A1c from screening to 3 and 6 months in each of the OneTouch Solutions programs
时间窗: 3 and 6 months
次要结局
- Change from baseline in patient activation measures as assessed by PAM-13 survey after 3 and 6 months(3 and 6 months)
- Change from baseline in well-being as assessed by the WHO-5 survey after 3 and 6 months(3 and 6 months)
- Change from baseline in diabetes distress as assessed by the diabetes distress scale (DDS) after 3 and 6 months(3 and 6 months)
- Change from baseline in medication adherence as assessed by a medication adherence survey after 3 and 6 months(3 and 6 months)
- Change in mean blood glucose derived from blood glucose testing throughout the study in each of the OneTouch Solutions programs(3 and 6 months)